Axios @axios
Pfizer's COVID-19 vaccine was granted priority review for full approval by the FDA for Americans 16 and older. The priority review shortens the approval process from 10 months to six months, with the goal date for a decision expected in January 2022. https://t.co/M6mc2UjBYo — PolitiTweet.org